Top Markets
Coin of the day
Nanobiotix S.A. Nanobiotix S.A.

Nanobiotix S.A.

NANO
株式のランク #5950
Nanobiotix S.A. operates as a clinical-stage biotechnology that focuses on... Nanobiotix S.A. operates as a clinical-stage biotechnology that focuses on developing product candidates for the treatment of cancer and other unmet medical needs. Its lead product candidate is NBTXR3, a sterile aqueous suspension of crystalline hafnium oxide nanoparticles used for the treatment of soft tissue sarcoma, head and neck cancers, liver cancers, prostate cancer, pancreatic cancer, esophageal cancer, rectal cancer, and non-small cell lung cancer. The company has a partnership with Lian Oncology Limited to develop and commercialize NBTXR3 in Greater China, South Korea, Singapore, and Thailand. Nanobiotix S.A. was incorporated in 2003 and is based in Paris, France.
株価
$45.79
時価総額
$2.33B
変化(1日)
11.43%
変化(1年)
408.10%
FR
取引 Nanobiotix S.A. (NANO)

カテゴリー

Nanobiotix S.A.(NANO)の配当利回りの履歴
Nanobiotix S.A.(銘柄コード: NANO)の配当利回り(TTM)は2026時点で0です。
過去5年間の平均配当利回り: 0.00%
Nanobiotix S.A.(NANO)の2026から2026までの配当利回りの履歴
各年末時点の配当利回り(TTM)
配当利回り 変化
提供された日付のデータは十分ではありません。
類似企業または競合他社の配当利回り(TTM)